Investors Buy Shares of Johnson & Johnson (JNJ) on Weakness on Insider Selling

Investors bought shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Tuesday after an insider sold shares in the company. $223.00 million flowed into the stock on the tick-up and $145.67 million flowed out of the stock on the tick-down, for a money net flow of $77.33 million into the stock. Of all companies tracked, Johnson & Johnson had the 16th highest net in-flow for the day. Johnson & Johnson traded down ($2.28) for the day and closed at $130.87Specifically, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the sale, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.19% of the company’s stock.

JNJ has been the subject of a number of recent research reports. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective for the company in a research note on Thursday, January 11th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a research note on Monday, January 22nd. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Finally, Stifel Nicolaus lifted their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $146.16.

The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. The company has a market capitalization of $351,584.88, a P/E ratio of 17.93, a PEG ratio of 2.19 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The firm had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. During the same period in the previous year, the firm earned $1.58 earnings per share. The company’s revenue was up 11.5% on a year-over-year basis. research analysts predict that Johnson & Johnson will post 8.11 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be paid a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.59%. Johnson & Johnson’s payout ratio is 861.54%.

A number of large investors have recently bought and sold shares of the business. Colonial Trust Advisors lifted its holdings in shares of Johnson & Johnson by 22.4% in the fourth quarter. Colonial Trust Advisors now owns 155,696 shares of the company’s stock valued at $21,754,000 after purchasing an additional 28,501 shares in the last quarter. Cedar Hill Associates LLC lifted its holdings in shares of Johnson & Johnson by 7.8% in the fourth quarter. Cedar Hill Associates LLC now owns 14,202 shares of the company’s stock valued at $1,984,000 after purchasing an additional 1,027 shares in the last quarter. Xact Kapitalforvaltning AB lifted its holdings in shares of Johnson & Johnson by 7.4% in the fourth quarter. Xact Kapitalforvaltning AB now owns 496,946 shares of the company’s stock valued at $69,433,000 after purchasing an additional 34,326 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of Johnson & Johnson by 8.2% in the fourth quarter. Handelsbanken Fonder AB now owns 632,946 shares of the company’s stock valued at $88,435,000 after purchasing an additional 47,820 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of Johnson & Johnson by 4.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 645,393 shares of the company’s stock valued at $90,173,000 after purchasing an additional 27,127 shares in the last quarter. 65.58% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/02/22/investors-buy-shares-of-johnson-johnson-jnj-on-weakness-on-insider-selling.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply